Central line-associated bloodstream infections: Effect of patient and pathogen factors on outcome

被引:0
|
作者
Arunan, Bharathi [1 ]
Ahmed, Nishat H. [2 ,4 ]
Kapil, Arti [2 ]
Vikram, Naval K. [3 ]
Sinha, Sanjeev [3 ]
Biswas, Ashutosh [3 ]
Satpathy, Gita [2 ]
Wig, Naveet [3 ]
机构
[1] All India Inst Med Sci, Dept Med & Microbiol, New Delhi, India
[2] All India Inst Med Sci, Dept Microbiol, New Delhi, India
[3] All India Inst Med Sci, Dept Med, New Delhi, India
[4] All India Inst Med Sci, Dr RP Ctr Ophthalm Sci, Ocular Microbiol Sect, New Delhi, India
关键词
Antimicrobial resistance; biofilm formation; central line-associated bloodstream infections; central line; INTENSIVE-CARE-UNIT; RISK-FACTORS; BIOFILM; EPIDEMIOLOGY; PERSISTENT; BACTERIAL;
D O I
10.4103/jgid.jgid_213_22
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Patients on central lines are often having multiple morbidities, and invasive devices provide a niche for biofilm formation, which makes central line-associated bloodstream infections (CLABSIs), a serious concern in health-care settings, as the infections difficult to treat. In this study, we evaluated the common bacteria causing CLABSI, and various patient and pathogen factors affecting the clinical outcome. Methods: In the prospective observational study, patients diagnosed with CLABSI were recruited. Extensive clinical, microbiological, and other laboratory workup was done, and observations were recorded. Congo red agar method, tube test, and microtiter plate assay were used for eliciting the biofilm-forming attributes of the bacterial pathogens.Results: Klebsiella pneumoniae was responsible for 48% of CLABSI, followed by Coagulase-negative Staphylococci (16%) and Staphylococcus aureus and Acinetobacter baumannii (12% each). Fifty-six percent of the isolates produced biofilms. The median (interquartile range) duration of hospital stay till death or discharge was 30 (20, 43) days. The all-cause mortality was 44%. Patients having a deranged liver function on the day of diagnosis (P value for total bilirubin 0.001 and for aspartate transaminase 0.02), and those infected with multidrug-resistant organisms (P value = 0.04) had significantly poor prognosis. The difference in the demographic, clinical, laboratory profile, and outcome of patients infected with biofilm producers and nonproducers was not found to be statistically significant.Conclusion: The study throws light on various host and pathogen factors determining the cause and outcome of CLABSI patients. To the best of our knowledge, this is the first study trying to decipher the role of biofilm formation in the virulence of pathogens and the prognosis of CLABSI.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 50 条
  • [1] Bloodstream Infections and Central Line-Associated Bloodstream Infections
    Watson, Christopher M.
    Al-Hasan, Majdi N.
    SURGICAL CLINICS OF NORTH AMERICA, 2014, 94 (06) : 1233 - +
  • [2] Factors Associated With Recurrence And Mortality In Central Line-Associated Bloodstream Infections
    Huerta, L. E.
    Nelson, G.
    Rice, T. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [3] Effect of Central Line Bundle Compliance on Central Line-Associated Bloodstream Infections
    Lee, Kyoung Hwa
    Cho, Nan Hyoung
    Jeong, Su Jin
    Kim, Mi Na
    Han, Sang Hoon
    Song, Young Goo
    YONSEI MEDICAL JOURNAL, 2018, 59 (03) : 376 - 382
  • [4] Preventing Central Line-Associated Bloodstream Infections
    Kusek, Linda
    JOURNAL OF NURSING CARE QUALITY, 2012, 27 (04) : 283 - 287
  • [5] Treatment of central line-associated bloodstream infections
    Jérémy Guenezan
    Bertrand Drugeon
    Nicolas Marjanovic
    Olivier Mimoz
    Critical Care, 22
  • [6] Prevention of Central Line-Associated Bloodstream Infections
    Tardy, Caroline
    Lasik, Emmie
    Jacobs, Frederic M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (24): : 2307 - 2308
  • [7] Prevention of Central Line-Associated Bloodstream Infections
    Bell, Taison
    O'Grady, Naomi P.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2017, 31 (03) : 551 - +
  • [8] Prevention of Central Line-Associated Bloodstream Infections
    O'Grady, Naomi P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (12): : 1121 - 1131
  • [9] Economics of central line-associated bloodstream infections
    Shannon, Richard P.
    Patel, Bhavin
    Cummins, Daniel
    Shannon, Alexander H.
    Ganguli, Gauthan
    Lu, Yee
    AMERICAN JOURNAL OF MEDICAL QUALITY, 2006, 21 (06) : 7S - 16S
  • [10] Treatment of central line-associated bloodstream infections
    Guenezan, Jeremy
    Drugeon, Bertrand
    Marjanovic, Nicolas
    Mimoz, Olivier
    CRITICAL CARE, 2018, 22